aminoimidazole carboxamide has been researched along with paclitaxel in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, PS | 1 |
| Geelen, MJ; Guzmán, M; Velasco, G | 1 |
| Kim, HI; Kim, HS; Kim, JH; Kim, N; Kim, SJ; Lee, HJ; Lee, JO; Lee, YW; Park, SH | 1 |
3 other study(ies) available for aminoimidazole carboxamide and paclitaxel
| Article | Year |
|---|---|
Biotechnology transfer at the National Institutes of Health.
Topics: Aminoimidazole Carboxamide; Antineoplastic Agents; Biotechnology; Ethics, Medical; Humans; Industry; National Institutes of Health (U.S.); Paclitaxel; Proteins; Research; Research Support as Topic; Technology Transfer; Tissue Inhibitor of Metalloproteinase-2; Triazoles; United States | 1993 |
Control of hepatic fatty acid oxidation by 5'-AMP-activated protein kinase involves a malonyl-CoA-dependent and a malonyl-CoA-independent mechanism.
Topics: Acetyl-CoA Carboxylase; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Caprylates; Carnitine O-Palmitoyltransferase; Enzyme Activation; Fatty Acids; In Vitro Techniques; Liver; Male; Malonyl Coenzyme A; Microtubules; Mitochondria, Liver; Multienzyme Complexes; Okadaic Acid; Oxidation-Reduction; Paclitaxel; Palmitates; Protein Kinases; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Ribonucleotides | 1997 |
Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1α and FOXO3a by AMPK signaling.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Breast Neoplasms; Cell Survival; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Paclitaxel; Peptide Elongation Factor 1; Signal Transduction | 2015 |